Attridge et al. 1 present an analysis of a complex data set, which offers important confirmation of the differences between the clinical presentation of spontaneous intestinal perforations (SIP) and surgical necrotizing enterocolitis (NEC). The pattern of disease is an important observation; however, several questions should be addressed before we accept the conclusion reached by the authors related to early indomethacin exposure.
In a three group matched analysis, the number of infants in each group should reflect a 1:1:1 match. Presuming that sites would have been internally consistent with their documentation of diagnosis such as Patent Ductus Arteriosus (PDA), SIP and NEC, the method of retrospective diagnosis assignment would be strengthened if infants were matched by site. Site matching would also balance other process level variation, which may have influenced outcomes. Matching by year of report would strengthen any conclusions, as the increasing report of SIP over time reflects clinicians increasing awareness of SIP, thus reducing the report of a presumed diagnosis of NEC without confirmation by review of pathology reports.
In the interpretation of the data, readers should be cautioned that not all treatment alternatives for the PDA were included. PDAs which were not treated with indomethacin may have been managed either conservatively or by ligation. The authors did not report the SIP rate associated with PDA ligation without exposure to indomethacin. If the SIP rate is higher in this subgroup it would bring more focus on clinically relevant PDAs rather than the treatment. Clinicians who interpret the authors report as suggesting that indomethacin use should be curtailed, might not just expose their patients to the higher risks of complications related to ligation, but increase their patient's risk of SIP.
In light of the shift of clinician's preference away from intubation as an early intervention for respiratory distress syndrome, the analysis of exposure of the gastrointestinal (GI) tract to positive pressure from interventions such as monitored CPAP, Nasal SIMV or unregulated pressures from high flow nasal cannula should have been more detailed. The rising frequency of reports of spontaneous perforations does appear to trend with the 'noninvasive' RDS management trend. The database may not allow this, but in a disorder associated with perforation of the GI tract, the inadvertent, but direct exposure of the GI tract to positive pressure should be considered. The current report only summarized this risk factor and does not provide enough detail regarding during what period of time, for how long and at what pressure, an infant was managed on positive pressure while not intubated in the first few days.
The analysis of these data in a complex retrospective study may offer new insights, however, as the authors clearly state, no randomized clinical trial has demonstrated that indomethacin alone, either as a treatment for the PDA or in the preventive strategy for intraventricular hemorrhage, is independently associated with SIP. No safer alternative for ductal management has been found, and without the inclusion of an analysis of the SIP rates in ligated infants, we should be very cautious in our application of these interesting findings. We thank Dr Bloom for his interest and concerns. Dr Bloom is familiar with the Pediatrix database and makes some excellent points for us to consider. He raises three primary concerns:
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(1) whether matching by site and year would have improved our analysis; (2) he suggests we investigate the potential confounder of CPAP; and (3) he disagrees with the conclusions drawn from the associations between early indomethacin and spontaneous intestinal perforation (SIP). First, Dr Bloom stated concerns about the design of our analysis. It was not our intent to match the surgical NEC patients to the SIP patients but instead to describe the demographic differences between two distinctive populations. Site variation in practice and process of care could have influenced the results as an unmeasured confounding variable; however, when included in multivariate analysis site was not a potential confounder.
Our original intent was to match the SIP patients using the following criteria: inborn status, estimated gestational age, discharge year, gender, and birth weight matching within 40 g, ±20 g). This matching strategy did not work because there were many cases that could not be matched with controls because inborn turned out to be a nonrandom variable (controls vs SIP group -87.6 vs 75.1%). Inborn status and year of birth were dropped as matching criteria. This improved the matching but some unmatched extremely immature and low birth weight infants remained, hence the lack of a 1:1 match between cases of SIP and controls. There were differences in the two groups with respect to year of discharge with the controls being more often drawn from the more contemporary years (more potential patients in the more recent years). The year and inborn status differences lead us to check our match pairs by univariate analysis by doing a multivariate analysis that included these variables. The results of those analyses are listed in Table 1 in the paper. We describe the limitations of this approach and agree that any retrospective study can only infer association not cause and effect relationships.
Second, Dr Bloom suggests the data set could be used to look for an association between early CPAP exposure and SIP. The postulate that continuous luminal distension pressure causes SIP, transmitted distally to the ileum after placement upon CPAP is not new, but Dr Bloom is correct in pointing out that the size of our data base should allow us to test it. We were able to capture data for days 0 to 2 for 96% of our controls and 89.2% or our SIP cohorts (presented in the supplement data B -available online). We found 7.2% of controls were on CPAP in the first 3 days of life vs 5% of SIP patients. This was not significantly different, nor did it trend in the appropriate direction.
To begin with Dr Bloom's third concern: although we did report an independent association between SIP and indomethacin, we concluded that this data were consistent with (and that the literature as a whole points towards) indomethacin being a corisk factor with corticosteroids for SIP.
1,2 Unfortunately, some stressed extremely low birth weight (ELBW) infants are clearly capable of precocious elevation of endogenous steroids, 2 and it seems likely that this subset, in combination to those exposed to early exogenous steroids, accentuate the indomethacin effect.
Dr Bloom makes the statement that no prospective randomized controlled trial of indomethacin has ever found an association with SIP. We have three cautions to relay: (1) No prospective trials completed before 2000 has ever included SIP as an a priori secondary outcome. (2) In our subsequent paper from this data set we demonstrate that it is the ELBW (<1000 g) infant who is at particular risk for postnatal exposure. 3 Earlier randomized trials that included larger birth weight infants would have had reduced incidence of a disease that is uncommon in less premature infants (hence the early conclusion that SIP was rare). (3) In the absence of exogenous steroid randomization, we doubt that a single trial would be sufficiently powered to detect the effect of indomethacin alone. The difficulty with studying SIP has always been in getting a clean cohort of sufficient size.
Finally, Dr Bloom raised concerns that we did not explore all possible therapeutic options as potential associations for SIP (thereby testing the possibility the underlying PDA is actually the predominant risk factor). This is a valid concern. As described in the paper, the diagnosis of a PDA was associated with the development of SIP. Since much of the early indomethacin was used prophylactically to prevent the PDA or IVH and the PDA was not diagnosed because it was 'prevented', the two effects (presence of a PDA and treatment of a PDA) were hard to separate. We note that other authors have made fairly compelling arguments against prophylactic indomethacin treatment for an asymptomatic PDA and some clinicians do not utilize this practice (and thus might ligate a symptomatic PDA in the first week of life without indomethacin use). 4 To address whether other forms of ductal therapy might also be associated with SIP, we examined the timing of PDA ligation both in the first week of life (as a surrogate for a symptomatic PDA) and at any time to determine if either variable was associated with SIP (data shown below). From our analysis, it does not appear that early ligation without indomethacin was an independent risk factor for the SIP (P>0.2 in multivariate analysis). This would argue against Dr Bloom's concern and in favor of indomethacin as the principle risk factor. On the other hand, we note that PDA ligation at any time (including the time period after perforation) was significantly associated with SIP. This finding is difficult to interpret, because it could signify that SIP makes the ductus more resistant to closure vs the opposing possibility that delayed treatment of a symptomatic ductus leads to SIP. A more refined data set will be needed to discern between these two competing hypotheses. Again, we thank Dr Bloom for the opportunity to clarify these points. While we acknowledge the limitations inherent in a retrospective analysis, this study is currently the most comprehensive look at SIP and its associated risk factors to date. Accordingly, we continue to conclude that early indomethacin exposure in the ELBW infant is associated with SIP.
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